Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Multiple Myeloma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia, Plasma Cell 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1Hemangioma, Cavernous, Central Nervous System 1Corneal Diseases 1Blood Protein Disorders 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × daratumumab × Clear all
NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
90 enrolled
BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡